Imatinib Front-Line Therapy Is Safe and Effective in Patients With Chronic Myelogenous Leukemia With Pre-Existing Liver and/or Renal Dysfunction

BACKGROUND: Imatinib 400 mg daily is the standard treatment for patients with chronic myelogenous leukemia (CML). The safety and efficacy of imatinib in CML patients with pre-existing liver and/or renal dysfunction has not been analyzed. METHODS: The authors analyzed the outcome of 259 patients with...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer
Egile Nagusiak: Tong, Wei-Gang, Kantarjian, Hagop, O'Brien, Susan, Faderl, Stefan, Ravandi, Farhad, Borthakur, Gautam, Shan, Jianqin, Pierce, Sherry, Rios, Mary Beth, Cortes, Jorge
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2010
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4314210/
https://ncbi.nlm.nih.gov/pubmed/20564631
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25071
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak